UK Pharma Claims Breakthrough On COVID Treatment

July 20, 2020 Coronavirus, Science

British pharmaceutical company Synairgen has claimed that its new respiratory coronavirus treatment has reduced the number of hospitalized Covid-19 patients needing intensive care in a clinical trial.

The company said its nebulizer treatment produced a 79% lower risk of patients developing severe disease than those given a placebo in initial trials.

Patients that received the treatment “were more than twice as likely to recover (defined as ‘no limitation of activities’ or ‘no clinical or virological evidence of infection’) over the course of the treatment period compared to those receiving placebo,” Synairgen claimed.

We are thrilled to announce positive topline #COVID19 results from our trial of #SNG001 in hospitalised patients. The trial of SNG001, inhaled #InterferonBeta, found patients who received SNG001 had a 79% lower risk of developing severe disease. Read here: https://t.co/Lat33hMn5f

— Synairgen (@Synairgenplc) July 20, 2020

Potential game changer inhaler drug, from Southampton based Synairgen sees its stock on an absolute tear. Up by 460% pic.twitter.com/e3ed55UYhJ

— Samantha Washington (@skynewsSam) July 20, 2020

“It’s like the conductor of an orchestra.”

Chief Executive of Synairgen Richard Marsden tells me how a new drug could cut the risk of severe COVID-19 symptoms by 79%. RC#KayBurley pic.twitter.com/HbBi2S8Y22

— Kay Burley (@KayBurley) July 20, 2020